31836454 29083112 33069860 34781798 31968213 30691064 31972133 31780366 31982038 33630023 31970198 28468798 31649958 28645365 33927727 30089715 29576315 30783984 34084173 34876153 29616042 31298581 34040605 30559260 32362898 30783972 32348718 3116797 - Search Results

Year	Number of Results
2017	4
2018	5
2019	12
2020	11
2021	8
2022	1

1

Adeno-associated viral vector-mediated immune responses: Understanding barriers to gene delivery.

Nidetz NF, McGee MC, Tse LV, Li C, Cong L, Li Y, Huang W. Nidetz NF, et al. Pharmacol Ther. 2020 Mar;207:107453. doi: 10.1016/j.pharmthera.2019.107453. Epub 2019 Dec 11. Pharmacol Ther. 2020. PMID: 31836454 Free PMC article. Review.

2

Immunity to CRISPR Cas9 and Cas12a therapeutics.

Chew WL. Chew WL. Wiley Interdiscip Rev Syst Biol Med. 2018 Jan;10(1). doi: 10.1002/wsbm.1408. Epub 2017 Oct 30. Wiley Interdiscip Rev Syst Biol Med. 2018. PMID: 29083112 Review.

3

Immune responses to retinal gene therapy using adeno-associated viral vectors - Implications for treatment success and safety.

Bucher K, Rodríguez-Bocanegra E, Dauletbekov D, Fischer MD. Bucher K, et al. Prog Retin Eye Res. 2021 Jul;83:100915. doi: 10.1016/j.preteyeres.2020.100915. Epub 2020 Oct 15. Prog Retin Eye Res. 2021. PMID: 33069860 Review.

4

Hemophilia A gene therapy: current and next-generation approaches.

Pipe SW, Gonen-Yaacovi G, Segurado OG. Pipe SW, et al. Expert Opin Biol Ther. 2022 Jan 6:1-17. doi: 10.1080/14712598.2022.2002842. Online ahead of print. Expert Opin Biol Ther. 2022. PMID: 34781798

5

Immune Responses to Viral Gene Therapy Vectors.

Shirley JL, de Jong YP, Terhorst C, Herzog RW. Shirley JL, et al. Mol Ther. 2020 Mar 4;28(3):709-722. doi: 10.1016/j.ymthe.2020.01.001. Epub 2020 Jan 10. Mol Ther. 2020. PMID: 31968213 Free PMC article. Review.

6

Adeno-associated Virus (AAV) versus Immune Response.

Rabinowitz J, Chan YK, Samulski RJ. Rabinowitz J, et al. Viruses. 2019 Jan 25;11(2):102. doi: 10.3390/v11020102. Viruses. 2019. PMID: 30691064 Free PMC article. Review.

7

AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer.

Verdera HC, Kuranda K, Mingozzi F. Verdera HC, et al. Mol Ther. 2020 Mar 4;28(3):723-746. doi: 10.1016/j.ymthe.2019.12.010. Epub 2020 Jan 10. Mol Ther. 2020. PMID: 31972133 Free PMC article. Review.

8

Type I IFN Sensing by cDCs and CD4⁺ T Cell Help Are Both Requisite for Cross-Priming of AAV Capsid-Specific CD8⁺ T Cells.

Shirley JL, Keeler GD, Sherman A, Zolotukhin I, Markusic DM, Hoffman BE, Morel LM, Wallet MA, Terhorst C, Herzog RW. Shirley JL, et al. Mol Ther. 2020 Mar 4;28(3):758-770. doi: 10.1016/j.ymthe.2019.11.011. Epub 2019 Nov 15. Mol Ther. 2020. PMID: 31780366 Free PMC article.

9

Muscle-Directed Delivery of an AAV1 Vector Leads to Capsid-Specific T Cell Exhaustion in Nonhuman Primates and Humans.

Gernoux G, Gruntman AM, Blackwood M, Zieger M, Flotte TR, Mueller C. Gernoux G, et al. Mol Ther. 2020 Mar 4;28(3):747-757. doi: 10.1016/j.ymthe.2020.01.004. Epub 2020 Jan 13. Mol Ther. 2020. PMID: 31982038 Free PMC article.

10

Characterization of Gene Therapy Associated Uveitis Following Intravitreal Adeno-Associated Virus Injection in Mice.

Tummala G, Crain A, Rowlan J, Pepple KL. Tummala G, et al. Invest Ophthalmol Vis Sci. 2021 Feb 1;62(2):41. doi: 10.1167/iovs.62.2.41. Invest Ophthalmol Vis Sci. 2021. PMID: 33630023 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results